fingolimod / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

9 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fingolimod / Generic mfg.
2004-000655-41: A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintained on a triple immunosuppressive regimen with either MPA or mTOR inhibitor

Ongoing
3
10
Europe
FTY720, FTY720,
Novartis Farmacéutica S.A
prevention of acute rejection in maintenance renal transplant recipients
 
 
PARADIGMS, NCT01892722 / 2011-005677-23: Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Checkmark PARADIGMS
Sep 2017 - Sep 2017: PARADIGMS
Recruiting
3
235
Europe, Canada, US, RoW
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Novartis Pharmaceuticals
Multiple Sclerosis
07/17
07/29
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-004431-24: A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis Estudio para evaluar la eficacia, seguridad, farmacocinética y farmacodinamia de ponesimod frente a fingolimod durante 108 semanas de tratamiento en pacientes pediátricos, de 10 a <18 años, con esclerosis múltiple remitente recurrente.

Ongoing
3
212
Europe, RoW
Ponesimod, Fingolimod, JNJ-67896153/ACT-128800, Film-coated tablet, Capsule, Gilenya hard capsules
Janssen-Cilag International NV, Janssen Research & Development, LLC
Relapsing-remitting Multiple Sclerosis Esclerosis múltiple remitente recurrente., Chronic inflammatory disease attacking the CNS Enfermedad inflamatoria crónica que ataca al SNC., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT06408259: Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Not yet recruiting
3
194
US
Ozanimod, Fingolimod, Placebo
Celgene
Multiple Sclerosis, Relapsing-Remitting
04/31
07/36
ARTIOS, NCT04353492 / 2019-001341-40: An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Active, not recruiting
3
564
Europe, Canada, US, RoW
Ofatumumab, OMB157
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
04/25
04/25
Operetta 2, NCT05123703 / 2020-004128-41: A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis

Recruiting
3
171
Europe, Canada, US, RoW
Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
Hoffmann-La Roche, PPD
Relapsing-Remitting Multiple Sclerosis
07/25
09/29
NEOS, NCT04926818 / 2020-002700-39: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Recruiting
3
120
Europe, Canada, US, RoW
Fingolimod, FTY720, Ofatumumab, OMB157, Siponimod, BAF312, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Novartis Pharmaceuticals
Multiple Sclerosis (MS)
03/27
12/31
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21

Download Options